ANTITRUST NEWS: FTC touts Caremark settlement will drive down patient…

The FTC settled with Caremark (CVS Health subsidiary), a major pharmacy benefit manager, requiring business practice changes including insulin price caps, increased transparency, and fair treatment of community pharmacies. The settlement locks in $8.5 billion in consumer savings over 10 years with potential additional $4.5 billion from point-of-sale rebates. If you're building community pharmacy tech or supply chain software, Caremark just lost the ability to use rebates and pricing opacity as a weapon against you. Independent pharmacies now have 10 years of regulatory cover to build a viable alternative to the PBM margin squeeze.